GDm -health . Empowering women to better manage their condition at home
GDm-Health is an app and back-end system for the management of gestational diabetes. The platform comprises a smartphone app, with a Bluetooth-enabled blood glucose meter, for the patient; and a secure website, with optimised data presentation and alerting algorithms for assigned healthcare professionals
- Allows effective management of GDm at home
- Reduces unnecessary hospital visits
- Enables midwives to care for the patients most in need
- Helps to deliver care to people who live in remote and rural areas
- Allows for better sharing of information to support integrated, joined-up, continuous care
- Empowers patients to take control of their own health
The UK is currently experiencing a rise in the prevalence of Gestational Diabetes, from a baseline of around 4% in 2008, predicted to reach over 16% in 2016.
Working with GDm, a Trust could reduce a proportion of face to face clinical / hospital visits from every 2 weeks to every 4 weeks; minimising the number of unwaranted appointments and consequently increasing the number of patients in need of support to be seen. GDm has been shown to reduce costs and improve efficiency by;
•reducing clinic visits by up to 26%
•reducing time spent by the diabetes midwives on clerical and administrative tasks by up to 50%
• Provide high user satisfaction (92% of patients using GDm until delivery)
• Provides real time communication between patient and healthcare professionals
Drayson Technologies has signed a five-year Strategic Research Agreement (SRA) with the University of Oxford (OU) and the Oxford University Hospitals NHS Foundation Trust (OUH). The OU and OUH have developed and trialled the technologies in the Oxford Biomedical Research Centre (BRC) funded by the National Institute for Health Research (NIHR).
The SRA and associated exclusive licensing arrangements ensure that the technologies can go into commercialisation stage so that they can bring benefit to patients across the NHS and overseas, and allows some of the profits to go back into the University of Oxford and the Oxford University Hospitals NHS Foundation Trust to fund more research and ultimately benefit more patients